Kyverna Therapeutics Announces Appointment of New Chief Financial Officer
Kyverna Therapeutics (Nasdaq: KYTX), a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases, has appointed Dr. Marc Grasso as its new Chief Financial Officer, effective June 30, 2025. Dr. Grasso brings over 25 years of experience in public company operations, capital markets, and investment banking.
Dr. Grasso previously served as CFO of Alector, Inc. and held the position of CFO and Chief Business Officer at Kura Oncology. His extensive background includes managing director roles at prominent institutions including Stifel, UBS, and Leerink Swann. He succeeds Ryan Jones, who will transition to a strategic advisor role.
As part of his appointment, Dr. Grasso will receive an inducement grant of options to purchase 450,000 shares of Kyverna's common stock, vesting over four years with 25% vesting after one year and the remainder vesting monthly thereafter.
Kyverna Therapeutics (Nasdaq: KYTX), una società biofarmaceutica in fase clinica specializzata nello sviluppo di terapie cellulari per malattie autoimmuni, ha nominato Dr. Marc Grasso come nuovo Chief Financial Officer, con decorrenza dal 30 giugno 2025. Il Dr. Grasso vanta oltre 25 anni di esperienza in operazioni di società quotate, mercati finanziari e investment banking.
In precedenza, il Dr. Grasso ha ricoperto il ruolo di CFO presso Alector, Inc. e quello di CFO e Chief Business Officer presso Kura Oncology. Il suo ampio background include posizioni da managing director in istituzioni di rilievo come Stifel, UBS e Leerink Swann. Succede a Ryan Jones, che assumerà un ruolo di consulente strategico.
In occasione della nomina, il Dr. Grasso riceverà una concessione incentivante di opzioni per l'acquisto di 450.000 azioni ordinarie di Kyverna, con maturazione su quattro anni: il 25% dopo un anno e il resto mensilmente successivamente.
Kyverna Therapeutics (Nasdaq: KYTX), una empresa biofarmacéutica en etapa clínica que desarrolla terapias celulares para enfermedades autoinmunes, ha nombrado a Dr. Marc Grasso como su nuevo Director Financiero, efectivo a partir del 30 de junio de 2025. El Dr. Grasso cuenta con más de 25 años de experiencia en operaciones de empresas públicas, mercados de capitales y banca de inversión.
Anteriormente, el Dr. Grasso se desempeñó como CFO de Alector, Inc. y ocupó los cargos de CFO y Director Comercial en Kura Oncology. Su amplia trayectoria incluye roles como director gerente en instituciones destacadas como Stifel, UBS y Leerink Swann. Sustituye a Ryan Jones, quien pasará a un rol de asesor estratégico.
Como parte de su nombramiento, el Dr. Grasso recibirá una concesión de incentivo de opciones para comprar 450,000 acciones ordinarias de Kyverna, que se consolidarán en un periodo de cuatro años, con un 25% consolidado tras un año y el resto de forma mensual posteriormente.
Kyverna Therapeutics (나스닥: KYTX)는 자가면역 질환 치료를 위한 세포 치료제를 개발하는 임상 단계의 바이오제약 회사로, 마크 그라소 박사를 2025년 6월 30일부로 새로운 최고재무책임자(CFO)로 임명했습니다. 그라소 박사는 공개 기업 운영, 자본 시장 및 투자 은행 분야에서 25년 이상의 경력을 보유하고 있습니다.
그라소 박사는 이전에 Alector, Inc.의 CFO를 역임했으며, Kura Oncology에서는 CFO 겸 최고사업책임자(CBO)로 근무했습니다. 또한 Stifel, UBS, Leerink Swann과 같은 주요 기관에서 전무이사(Managing Director)로 활동한 경험이 있습니다. 그는 전략 고문 역할로 전환할 라이언 존스의 후임입니다.
임명과 함께 그라소 박사는 Kyverna의 보통주 450,000주 매수 옵션을 인센티브로 부여받으며, 이는 4년에 걸쳐 권리가 부여되며 1년 후 25%가 부여되고 이후 매월 나머지가 부여됩니다.
Kyverna Therapeutics (Nasdaq : KYTX), une entreprise biopharmaceutique en phase clinique développant des thérapies cellulaires pour les maladies auto-immunes, a nommé Dr Marc Grasso en tant que nouveau Directeur Financier, à compter du 30 juin 2025. Le Dr Grasso apporte plus de 25 ans d'expérience dans les opérations de sociétés cotées, les marchés financiers et la banque d'investissement.
Le Dr Grasso a précédemment occupé le poste de CFO chez Alector, Inc. et a été CFO et Directeur Commercial chez Kura Oncology. Son parcours étendu inclut des postes de directeur général dans des institutions renommées telles que Stifel, UBS et Leerink Swann. Il succède à Ryan Jones, qui passera à un rôle de conseiller stratégique.
Dans le cadre de sa nomination, le Dr Grasso recevra une attribution incitative de options d'achat de 450 000 actions ordinaires de Kyverna, acquises sur une période de quatre ans, avec 25 % acquises après un an et le reste acquis mensuellement par la suite.
Kyverna Therapeutics (Nasdaq: KYTX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das Zelltherapien für Autoimmunerkrankungen entwickelt, hat Dr. Marc Grasso zum neuen Chief Financial Officer ernannt, wirksam ab dem 30. Juni 2025. Dr. Grasso bringt über 25 Jahre Erfahrung in der Leitung börsennotierter Unternehmen, Kapitalmärkten und Investment Banking mit.
Dr. Grasso war zuvor CFO bei Alector, Inc. und hatte die Positionen CFO und Chief Business Officer bei Kura Oncology inne. Sein umfangreicher Hintergrund umfasst leitende Positionen bei namhaften Institutionen wie Stifel, UBS und Leerink Swann. Er folgt auf Ryan Jones, der in eine strategische Beraterrolle wechseln wird.
Im Rahmen seiner Ernennung erhält Dr. Grasso eine Anreizzuteilung von Optionen zum Kauf von 450.000 Aktien der Kyverna-Stammaktien, die über vier Jahre mit einer 25%igen Vesting-Rate nach einem Jahr und der restlichen monatlichen Vesting danach gewährt werden.
- None.
- None.
Dr. Marc Grasso brings more than 25 years of public company, capital markets and investment banking expertise to the role
"We are excited to welcome Marc, an accomplished life-sciences leader with a proven track record working in capital markets and driving financial discipline and operational execution in maturing public companies," said Warner Biddle, Chief Executive Officer of Kyverna Therapeutics. "As we continue to accelerate our clinical development and commercialization efforts, Marc's leadership will be instrumental in supporting our next phase of growth and advancing our mission to bring the transformative potential of CAR T-cell therapy to patients with autoimmune diseases. On behalf of the Kyverna leadership team, I'd also like to thank Ryan, one of Kyverna's first employees, for the significant contributions he has made throughout his tenure with the Company."
Most recently, Dr. Grasso served as CFO of Alector, Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, where he oversaw Financial Planning and Analysis, Investor Relations, Accounting, Information Technology and Facilities. Prior to Alector, Dr. Grasso held the position of CFO and Chief Business Officer of Kura Oncology. At these companies, Dr. Grasso was instrumental in optimizing capital allocation, strategic alliances, partnerships and licensing transactions.
Dr. Grasso has also held several leadership roles in the investment banking sector, including as Managing Director at Stifel, where he was responsible for building and managing the west coast life sciences and biotechnology investment banking business. He also held roles as Managing Director of Investment Banking in the Global Healthcare Group at UBS, focused on the biotechnology sector, and as Managing Director of Investment Banking at Leerink Swann, where he was instrumental in the west coast expansion of their franchise. Dr. Grasso joined Leerink from Morgan Stanley and held earlier positions in the global healthcare group of Credit Suisse First Boston and at Deutsche Banc Alex. Brown. During his Wall Street career, Dr. Grasso cultivated a strong network and deep understanding of the life sciences industry.
"I am thrilled to join Kyverna at this dynamic time and help accelerate the next critical phase of growth for the Company," said Dr. Grasso. "I look forward to leveraging my experience to contribute to Kyverna's goal of bringing the first CAR T-cell therapy for autoimmune disease to market and drive business and financial strategies that support the Company's mission."
Dr. Grasso received his medical degree from Johns Hopkins University School of Medicine, where he performed research in molecular oncology. He obtained a Bachelor of Arts degree in molecular biology with honors from
Inducement Grant
In connection with the appointment of Dr. Grasso as Kyverna's Chief Financial Officer, on June 30, 2025, Kyverna will grant Dr. Grasso an option to purchase 450,000 shares of its common stock (Option). The Option will be granted pursuant to the Kyverna Therapeutics, Inc. 2024 Inducement Equity Incentive Plan, as approved by the Compensation Committee of Kyverna's Board of Directors on September 14, 2024, and will be granted as an inducement material to Dr. Grasso's employment with Kyverna in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price of the Option will be the closing price of Kyverna's common stock on June 30, 2025, the date of grant. The Option will vest over four years, with
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating patients through the curative potential of cell therapy. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through late-stage clinical development with registrational trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase 1/2 trials for patients with lupus nephritis. The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Additionally, its pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats, including efficiently expanding into broader autoimmune indications and the potential to increase patient reach with KYV-102 using its proprietary whole blood rapid manufacturing process. For more information, please visit https://kyvernatx.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: Kyverna's commercialization efforts, next phase of growth and pipeline advancements; Kyverna's mission to bring the transformative potential of CAR-T cell therapy to patients with autoimmune diseases; the potential for Kyverna to bring the first CAR T-cell therapy for autoimmune disease to market; the potential for Kyverna to increase patient reach with KYV-102; and Kyverna's clinical trials, investigator-initiated trials and named-patient activities. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the
For more information, please visit https://kyvernatx.com.
Contact:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/kyverna-therapeutics-announces-appointment-of-new-chief-financial-officer-302493994.html
SOURCE Kyverna Therapeutics
FAQ
Who is the new CFO of Kyverna Therapeutics (KYTX)?
What is Dr. Marc Grasso's background before joining Kyverna (KYTX)?
What compensation package was announced for Kyverna's (KYTX) new CFO?
What is Kyverna Therapeutics' (KYTX) main business focus?
Who did Dr. Marc Grasso replace as CFO of Kyverna (KYTX)?
